0000899243-20-034529.txt : 20201218
0000899243-20-034529.hdr.sgml : 20201218
20201218180622
ACCESSION NUMBER: 0000899243-20-034529
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201208
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Machatha Stephen
CENTRAL INDEX KEY: 0001836354
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 201401847
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-12-08
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001836354
Machatha Stephen
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE, SUITE 320
LEXINGTON
MA
02421
0
1
0
0
Chief Development Officer
Common Stock
20091
D
Common Stock
211
I
See Footnote
Employee Stock Option (Right to Buy)
4.60
2026-04-05
Common Stock
35000
D
Employee Stock Option (Right to Buy)
5.25
2027-03-09
Common Stock
26200
D
Employee Stock Option (Right to Buy)
8.35
2028-02-28
Common Stock
45573
D
Employee Stock Option (Right to Buy)
8.05
2029-03-04
Common Stock
32000
D
Employee Stock Option (Right to Buy)
8.05
2029-03-04
Common Stock
31000
D
Employee Stock Option (Right to Buy)
3.78
2030-03-01
Common Stock
135560
D
These shares are held directly by Dr. Machatha's spouse. Dr. Machatha disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes.
The shares subject to this option shall vest over 4 years of service following January 8, 2016, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2017.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020.
/s/ Stephen Machatha
2020-12-18